Language

CAS NO:244767-67-7 Dapivirine (TMC120)

CAS NO:244767-67-7 NAME:Dapivirine (TMC120) MF：C20H19N5 MW：329.4 PURITY:98% COA:Provide Sample:Available Appearance:off white solid

Categories：

Life Science Chemicals

Pharmaceutical Intermediates

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

PRODUCT NAME	Dapivirine (TMC120)
CAS NO	244767-67-7
MP	218-222°C
BP	557.9±60.0 °C(Predicted)
DENSITY	1.23±0.1 g/cm3(Predicted)
STORAGE	2-8°C
DELIVERY	2-3DAYS
PACKAGE	According client's request

Synonyms:
4-[[4-[(2,4,6-Trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile
R 147681
TMC 120

Description of Dapivirine CAS NO:244767-67-7

Dapivirine CAS NO:244767-67-7 is an antiviral drug of the non-nucleoside reverse transcriptase inhibitor class. It was developed for the potential treatment and prevention of HIV infection in humans by acting as a competitive inhibitor of the viral enzyme reverse transcriptase. This drug has been shown to have anti-HIV activity in vivo, and was found to be safe even at high doses in animals. Dapivirine is also active against herpes simplex virus type 2 (HSV-2). The molecule was originally synthesized in 1979, but it took until 2006 before it was approved for human clinical trials. In vitro studies show that dapivirine inhibits the transcriptional regulation of HIV-1 LTR and prevents replication of HIV-1 RNA.

Dapivirine CAS NO:244767-67-7 is a non-nucleoside reverse transcriptase inhibitor developed at Janssen Therapeutics . It has been studied as a way of preventing infection by the human immunodeficiency virus in women . A monthly intravaginal ring containing dapivirine has been developed for this purpose .

Applications of Dapivirine CAS NO:244767-67-7

1)HIV-1 Prevention in Women
Dapivirine has been evaluated for its effectiveness in preventing HIV-1 infection among women through the use of a vaginal ring.

2)Development of Vaginal Film
Further expanding its application, Dapivirine has been developed into a quick-dissolving vaginal film for prevention of HIV-1 sexual transmission.

3)Pharmacokinetic Studies
Pharmacokinetic studies of Dapivirine vaginal microbicide gels have provided critical insights into the drug's safety and delivery mechanisms. These studies have shown that Dapivirine can be delivered to the lower genital tract at concentrations significantly higher than its in vitro inhibitory concentrations, suggesting effective protection against HIV infection with minimal systemic exposure

Future Directions
The World Health Organization has recommended that the dapivirine vaginal ring may be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches . Research is also underway to develop a vaginal ring that includes both contraception and HIV prevention

Key words: